Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Receives Health Canada Clearance to Begin Phase 2a Study with Montelukast Versafilm(TM) in Mild to Moderate Alzheimer's Disease

MarketWire Canada December 15, 2017

IntelGenx Receives USPTO Notice of Allowance for Montelukast Orange Book Eligible Patent

Marketwired December 11, 2017

IIROC Trading Resumption - IGX; IGX.DB

Canada NewsWire December 5, 2017

IIROC Trade Resumption - IntelGenx Technologies Corp.

Newsfile December 5, 2017

IntelGenx to Regain Exclusive Worldwide Rights to Develop and Commercialize RIZAPORT(R)

MarketWire Canada December 5, 2017

IIROC Trading Halt - IGX IGX.DB

Canada NewsWire December 5, 2017

IIROC Trade Halt - IntelGenx Technologies Corp.

Newsfile December 5, 2017

IntelGenx Submits Montelukast VersaFilm(TM) Clinical Trial Application With Health Canada

Marketwired November 9, 2017

IntelGenx Reports Third Quarter 2017 Financial Results

Marketwired November 9, 2017

IntelGenx to Report Third Quarter 2017 Financial Results on November 9, 2017 - Conference Call to Follow

MarketWire Canada November 2, 2017

IntelGenx and RedHill Biopharma Resubmit RIZAPORT® New Drug Application to the FDA

MarketWire Canada November 1, 2017

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines

GlobeNewswire November 1, 2017

IntelGenx Announces Decisions in Suboxone(R) Patent Litigation

MarketWire Canada September 6, 2017

IntelGenx Grants Stock Options

MarketWire Canada August 31, 2017

IntelGenx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

MarketWire Canada August 30, 2017

IntelGenx Reports Second Quarter 2017 Financial Results

MarketWire Canada August 10, 2017

Investor Network: Intelgenx Technologies Corp. to Host Earnings Call

Accesswire August 10, 2017

IntelGenx Closes Second Tranche of Convertible Debenture Offering

Marketwired August 8, 2017

IntelGenx to Report Second Quarter 2017 Financial Results on August 10, 2017 - Conference Call to Follow

Marketwired August 3, 2017

IntelGenx Presents at BIT's 7th Annual International Symposium of Drug Delivery Systems

MarketWire Canada July 12, 2017